Viewing Study NCT06565741



Ignite Creation Date: 2024-10-26 @ 3:38 PM
Last Modification Date: 2025-12-17 @ 8:09 AM
Study NCT ID: NCT06565741
Status: None
Last Update Posted: 2025-06-22 00:00:00
First Post: 2024-08-13 00:00:00

Brief Title: EEAP Using Moses 2.0 Technology vs the Thulium Fiber Laser in Medium-Large Prostates
Sponsor: None
Organization: Fundacio Puigvert

Study Overview

Official Title: Prospective and Randomized Analysis of Endoscopic Prostate Enucleation Using Moses 2.0 Technology Versus the New Thulium Fiber Laser in Medium and Large Prostates.
Status: None
Status Verified Date: 2025-06
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Surgery and Follow-up Schedule

* Surgeries will be performed between September 2024 and September 2025.
* Initial follow-up at 3 months.
* Completion of the first phase of the study: March 2026.

Scheduled of Visits: Selection Visit, 1-Month Postoperative Visit, 3-Month Follow-up, 6-Month Follow-up, Annual Follow-up Visit (1-3 years).

Sample size calculation was done using the main outcome variable (total surgical time). Previous studies indicate that surgical time for ThuFLEP is 71.6 minutes \[8\]. The time for MoLEP may be at least 5 minutes less. Accepting an alpha risk of 5% and a beta risk of 20% in a two-tailed test, a total of 120 patients are needed (60 in each study group). A common standard deviation of 9 minutes change is assumed. A loss to follow-up rate of 15% has been estimated.

Randomization between the two surgery groups will be performed using the Efron procedure to balance the groups in terms of the number of subjects. The calculation will be carried out with the !RndSeq macro for SPSS Statistics. It will be conducted centrally by a person independent of the surgeon.

Statistical Analysis: For quantitative variables, measures of central tendency and dispersion will be .provided. Normality tests will be conducted using the Shapiro-Wilk test. For qualitative variables, valid percentages will be shown. Sociodemographic and clinical data, as well as the main study variables, will be compared between study groups using the Student's t-test (Mann-Whitney U test in case of non-normality). Chi-square test or Fisher's test (if any observed frequency is \<5) will be used for qualitative variables. A multivariate linear regression model will be constructed to determine variables related to surgical time. Beta coefficients and 95% confidence intervals (CI) will be determined. A preliminary study will be conducted on potential confounding and interacting factors. Adjustment will be made for clinically or bibliographically relevant variables. Interaction will be tested using the likelihood ratio test. A significant difference will be accepted in all tests with a p-value \<0.05. R Studio statistical package (V2.5.1) will be used for data analysis.
Detailed Description: Surgery and Follow-up Schedule

Surgeries will be performed between September 2024 and September 2025
Initial follow-up at 3 months
Completion of the first phase of the study March 2026

Scheduled of Visits Selection Visit 1-Month Postoperative Visit 3-Month Follow-up 6-Month Follow-up Annual Follow-up Visit 1-3 years

Sample size calculation was done using the main outcome variable total surgical time Previous studies indicate that surgical time for ThuFLEP is 716 minutes 8 The time for MoLEP may be at least 5 minutes less Accepting an alpha risk of 5 and a beta risk of 20 in a two-tailed test a total of 120 patients are needed 60 in each study group A common standard deviation of 9 minutes change is assumed A loss to follow-up rate of 15 has been estimated

Randomization between the two surgery groups will be performed using the Efron procedure to balance the groups in terms of the number of subjects The calculation will be carried out with the RndSeq macro for SPSS Statistics It will be conducted centrally by a person independent of the surgeon

Statistical Analysis For quantitative variables measures of central tendency and dispersion will be provided Normality tests will be conducted using the Shapiro-Wilk test For qualitative variables valid percentages will be shown Sociodemographic and clinical data as well as the main study variables will be compared between study groups using the Students t-test Mann-Whitney U test in case of non-normality Chi-square test or Fishers test if any observed frequency is 5 will be used for qualitative variables A multivariate linear regression model will be constructed to determine variables related to surgical time Beta coefficients and 95 confidence intervals CI will be determined A preliminary study will be conducted on potential confounding and interacting factors Adjustment will be made for clinically or bibliographically relevant variables Interaction will be tested using the likelihood ratio test A significant difference will be accepted in all tests with a p-value 005 R Studio statistical package V251 will be used for data analysis

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None